Archive
594 articles, sorted by publication time.
BBM-P002 uses an AAV vector to deliver two key dopamine-synthesis enzymes into the putamen. Phase 1 12-month data showed no dose-limiting toxicity; this is an early safety signal, not a definitive conclusion on efficacy.
A small randomized feasibility trial moved deep brain stimulation from “continuous playback” toward “gait-adjusted” stimulation. The results show that the device can align with walking rhythm according to individual neural signals and reduced falls in a small number of patients; however, this remains a technical validation, not a definitive conclusion on efficacy.
For patients with chronic urticaria that recurs repeatedly and has hard-to-identify causes, relieving itch and clearing wheals is often more than a matter of comfort. Novartis has announced results from two Phase 3 studies pointing to an oral small-molecule therapy targeting immune signaling, but full data and long-term safety remain key to interpretation.
mNEXSPIKE lowers the mRNA dose to a fraction of existing products while using a more precise antigen design to seek similar protection; the approval is not just another vaccine, but also reflects how COVID-19 booster vaccination is moving toward a more limited, more stratified era.
The long-acting monoclonal antibody is approved for newborns and infants entering their first RSV season, adding a fixed-dose option for pediatric respiratory protection; its clinical positioning will depend on how policy recommendations, supply, and payment arrangements are implemented.
An infant with severe CPS1 deficiency received an in vivo base-editing treatment designed specifically for his mutation, with the process from diagnosis to clinical use completed in about six months. This is not a routine therapy that can be immediately replicated, but it pushes the treatment imagination for ultra-rare diseases toward a new clinical frontier.
The FDA approved Gilead’s lenacapavir for pre-exposure prophylaxis, giving high-risk adults and adolescents another option: an injection once every six months. It may lower the barrier of daily pill-taking while pushing issues of price, testing, and access to the front line of public health.
Delivering a functional gene into the brain through a neurosurgical approach brings a rare therapeutic attempt for WOREE syndrome; however, currently public information remains limited to a single case and short-term results, and broad adoption is still far from reach pending lengthy validation.
A phase 3 trial and ASCO presentation have rapidly raised the profile of this oral RAS inhibitor; the FDA has opened expanded access, but a true new standard still awaits completion of a full review.
The financing, reported as the largest biotech IPO in history, highlights investors’ continued strong interest in next-generation cancer drug platforms that can enter cells and tackle hard-to-drug proteins; however, public information is limited, and whether the platform can translate into clinical efficacy remains to be verified.
The FDA has allowed bemotrizinol for use in U.S. over-the-counter sunscreen products, giving U.S. sunscreen formulations an additional UV filter option covering both UVA and UVB; this rare update also highlights the public health and product design gaps left after years of stagnation in sunscreen ingredient regulation.
The research team presented at the European Society of Human Genetics conference. Using brain organoids built from cells of patients with DHDDS-related disease, they observed possible disease mechanisms and indicated that nicotinamide mononucleotide may have a chance to slow the disease course; however, this remains early-stage research, and efficacy and safety still need confirmation in clinical trials.